<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/blogpost.css">
    <link rel="stylesheet" href="css/mobile.css">
    <title>sBlog-Heaven for bloggers</title>

    <script src="https://unpkg.com/sharect@2.0.0/dist/sharect.js"></script>
    <!-- <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=6467a8a9ea134c0019b9b2e4&product=inline-share-buttons' async='async'></script> -->
</head>

<body>


    <nav class="navigation max-width-1 m-auto">
        <div class="nav-left">
            <a href="/">
                <span><img src="img/th.jfif"></span>

            </a>
            <ul>
                <li><a href="/">Home</a></li>
                <li><a href="#">About</a></li>
                <li><a href="/contact.html">Contact</a></li>
            </ul>

        </div>
        <div class="nav-right">
            <form action="/search.html" method="get">
                <input class="form-input" type="text" name="Query" placeholder="Article Search">
                <button class="btn">Search</button>
            </form>
        </div>
    </nav>

    <div class="max-width-1 m-auto">
        <hr>
    </div>

    <div class="post-img">
        <img src="img/men.jpg" alt="">
    </div>
    <br>
    <div class="m-auto  blog-post-content max-width-2 m-auto my-2 ">
        <h1 class="font1">The heaven for bloggers</h1>
        <br>
        <h3 class="blogpost-meta" style="color: purple;">MEN'S HEALTH</h3>
        <h1 class="blogpost-meta">FDA approves new treatment for advanced prostate cancer</h1>
        <br>
        <h2 class="blogpost-meta" style="font-family:'Gill Sans', 'Gill Sans MT', Calibri, 'Trebuchet MS', sans-serif">
            The treatment offers new hope for men who test positive for mutations affecting BRCA
            and other DNA-repair genes.</h2>
        <br>
        <img src="img/fda.jpg" alt="" class="blogpost-meta">
        <div class="blogpost-meta">
            <div class="author-info" style="font-size: 18px;">
                <div>
                    <b>
                        Author- Sandhya(abc)
                    </b>
                </div>
                <div>22 August. 8min read</div>
            </div>
            <div class="social">

                <svg width="24" height="24" viewBox="0 0 24 24" fill="none" class="ke">
                    <path
                        d="M20 5.34c-.67.41-1.4.7-2.18.87a3.45 3.45 0 0 0-5.02-.1 3.49 3.49 0 0 0-1.02 2.47c0 .28.03.54.07.8a9.91 9.91 0 0 1-7.17-3.66 3.9 3.9 0 0 0-.5 1.74 3.6 3.6 0 0 0 1.56 2.92 3.36 3.36 0 0 1-1.55-.44V10c0 1.67 1.2 3.08 2.8 3.42-.3.06-.6.1-.94.12l-.62-.06a3.5 3.5 0 0 0 3.24 2.43 7.34 7.34 0 0 1-4.36 1.49l-.81-.05a9.96 9.96 0 0 0 5.36 1.56c6.4 0 9.91-5.32 9.9-9.9v-.5c.69-.49 1.28-1.1 1.74-1.81-.63.3-1.3.48-2 .56A3.33 3.33 0 0 0 20 5.33"
                        fill="#A8A8A8"></path>
                </svg>
                <svg width="24" height="24" viewBox="0 0 24 24" fill="none" class="ke">
                    <path
                        d="M19.75 12.04c0-4.3-3.47-7.79-7.75-7.79a7.77 7.77 0 0 0-5.9 12.84 7.77 7.77 0 0 0 4.69 2.63v-5.49h-1.9v-2.2h1.9v-1.62c0-1.88 1.14-2.9 2.8-2.9.8 0 1.49.06 1.69.08v1.97h-1.15c-.91 0-1.1.43-1.1 1.07v1.4h2.17l-.28 2.2h-1.88v5.52a7.77 7.77 0 0 0 6.7-7.71"
                        fill="#A8A8A8"></path>
                </svg>

                <svg width="24" height="24" viewBox="0 0 24 24" fill="none" class="ke">
                    <path
                        d="M19.75 5.39v13.22a1.14 1.14 0 0 1-1.14 1.14H5.39a1.14 1.14 0 0 1-1.14-1.14V5.39a1.14 1.14 0 0 1 1.14-1.14h13.22a1.14 1.14 0 0 1 1.14 1.14zM8.81 10.18H6.53v7.3H8.8v-7.3zM9 7.67a1.31 1.31 0 0 0-1.3-1.32h-.04a1.32 1.32 0 0 0 0 2.64A1.31 1.31 0 0 0 9 7.71v-.04zm8.46 5.37c0-2.2-1.4-3.05-2.78-3.05a2.6 2.6 0 0 0-2.3 1.18h-.07v-1h-2.14v7.3h2.28V13.6a1.51 1.51 0 0 1 1.36-1.63h.09c.72 0 1.26.45 1.26 1.6v3.91h2.28l.02-4.43z"
                        fill="#A8A8A8"></path>
                </svg>
                <!-- <button class="af ag ah ai aj ak al am an ao ap aq ar as at ra q afx" aria-label="Share on linkedin"><svg width="24" height="24" viewBox="0 0 24 24" fill="none" class="ke"><path d="M19.75 5.39v13.22a1.14 1.14 0 0 1-1.14 1.14H5.39a1.14 1.14 0 0 1-1.14-1.14V5.39a1.14 1.14 0 0 1 1.14-1.14h13.22a1.14 1.14 0 0 1 1.14 1.14zM8.81 10.18H6.53v7.3H8.8v-7.3zM9 7.67a1.31 1.31 0 0 0-1.3-1.32h-.04a1.32 1.32 0 0 0 0 2.64A1.31 1.31 0 0 0 9 7.71v-.04zm8.46 5.37c0-2.2-1.4-3.05-2.78-3.05a2.6 2.6 0 0 0-2.3 1.18h-.07v-1h-2.14v7.3h2.28V13.6a1.51 1.51 0 0 1 1.36-1.63h.09c.72 0 1.26.45 1.26 1.6v3.91h2.28l.02-4.43z" fill="#A8A8A8"></path></svg><div class="px hv">Share on LinkedIn</div></button> -->


            </div>

        </div>
        <br><br>
        <br><br>

        <p class="font1">
            In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have
            this
            condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic
            options, so the approval helps to fill an urgent need.
            <br><br>
            mCRPC sets in when the front-line hormonal therapies that doctors use first for treating metastatic prostate
            cancer stop working. These drugs limit the body's production of testosterone, a hormone that fuels prostate
            cancer growth. If they are no longer effective, then doctors switch to a different class of drugs known as
            anti-androgens that further inhibit testosterone by blocking its cell receptor. One of those drugs is called
            enzalutamide.
            <br><br>
            The newly approved treatment combines enzalutamide with a second drug, talazoparib, that was already on the
            market for female cancer patients who test positive for BRCA mutations. These inherited gene defects boost
            risks
            for breast and ovarian cancer, but they can also elevate risks for prostate cancer in men. Indeed, an
            estimated
            10% of men with metastatic prostate cancer are BRCA-positive.
            <br><br>
            Talazoparib inhibits a DNA-repair system called PARP that the tumor cells need to keep their own genes in
            working order. When PARP is blocked by treatment, the cancer cells will eventually die. Other PARP
            inhibitors,
            including olaparib and rucaparib, are already approved for advanced prostate cancer in BRCA-positive men.
            <br><br>
            During research leading to this latest approval, 399 men with mCRPC were randomly divided into two groups.
            One
            group received talazoparib plus enzalutamide; the other group was treated with enzalutamide plus placebo.
            The
            men averaged 70 years in age, and most of them had already been treated with chemotherapy and/or a different
            anti-androgen called abiraterone. All the men were positive for either BRCA mutations or defects affecting
            other
            DNA-repair genes.
        </p>


    </div>
    <br>
    <div class="max-width-1 m-auto">
        <hr>
    </div>
    <div class="home-articles max-width-1 m-auto font2">
        <h2>People who read this article</h2>
        <div class="row">


            <div class="home-article post">
                <div class="home-article-img">
                    <img src="img/fda.jpg" alt="article">
                </div>
                <div class="home-article-content font1 center">
                    <a href="/men.html">
                        <h4 style="color: purple;">Proteins</h4>
                        <h3>Lorem ipsum dolor sit, amet consectetur adipisicing.</h3>
                    </a>
                    <div>Author Name</div>
                    <span>22 August | 8min Read</span>
                </div>
            </div>


            <div class="home-article post">
                <div class="home-article-img">
                    <img src="img/teen1.jpg" alt="article">
                </div>
                <div class="home-article-content font1 center">
                    <a href="/blog.html">
                        <h4 style="color: purple;">Child & Teen Health</h4>
                        <h3>Ringworm: What to know and do</h3>
                    </a>
                    <div>Author Name</div>
                    <span>23 May | 8min Read</span>
                </div>
            </div>




            <div class="home-article post">
                <div class="home-article-img">
                    <img src="img/14.jpg" alt="article">
                </div>
                <div class="home-article-content font1 center">
                    <a href="/vitamins.html">
                        <h4 style="color: purple;"> Vitamines</h4>
                        <h3>Who needs vitamins and supplements?</h3>

                    </a>
                    <div>Author Name</div>
                    <span>22 August | 8min Read</span>
                </div>
            </div>

        </div>
    </div>


    <!-- <div class="footer max-width-2 m-auto"> -->
    <div class="footer">

        <p>Copyright &paste sBlog.com</p>
        <a href="https://www.vacteezy.com/free-vector/typewritter">Typewriter Vectors by
            Vecteezy
        </a>
    </div>
    <script>
        Sharect.appendCustomShareButtons([{
            icon: '<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 478.165 478.165"><path d="M478.165 232.946c0 128.567-105.057 232.966-234.679 232.966-41.102 0-79.814-10.599-113.445-28.969L0 478.165l42.437-125.04c-21.438-35.065-33.77-76.207-33.77-120.159C8.667 104.34 113.763 0 243.485 0c129.623 0 234.68 104.34 234.68 232.946zM243.485 37.098c-108.802 0-197.422 87.803-197.422 195.868 0 42.915 13.986 82.603 37.576 114.879l-24.586 72.542 75.849-23.968c31.121 20.481 68.457 32.296 108.583 32.296 108.723 0 197.323-87.843 197.323-195.908 0-107.886-88.6-195.709-197.323-195.709zM361.931 286.62c-1.395-2.331-5.22-3.746-10.898-6.814-5.917-2.849-34.089-16.497-39.508-18.37-5.16-1.913-8.986-2.849-12.811 2.829-4.005 5.638-14.903 18.629-18.23 22.354-3.546 3.785-6.854 4.264-12.552 1.435-5.618-2.809-24.267-8.866-46.203-28.391-17.055-15.042-28.67-33.711-31.997-39.508-3.427-5.758-.398-8.826 2.471-11.635 2.69-2.59 5.778-6.734 8.627-10.041 2.969-3.287 3.905-5.638 5.798-9.424 1.913-3.905.936-7.192-.478-10.141-1.415-2.849-13.01-30.881-17.752-42.337-4.841-11.416-9.543-9.523-12.871-9.523-3.467 0-7.212-.478-11.117-.478-3.785 0-10.041 1.395-15.381 7.192-5.2 5.658-20.123 19.465-20.123 47.597 0 28.052 20.601 55.308 23.55 59.053 2.869 3.785 39.747 63.197 98.303 86.07 58.476 22.872 58.476 15.321 69.115 14.365 10.38-.956 34.069-13.867 38.811-27.096 4.66-13.45 4.66-24.766 3.246-27.137z"/></svg>',
            url: 'https://api.whatsapp.com/send?text=TEXT_SELECTION%20PAGE_URL'
        }, {
            icon: '<svg xmlns="http://www.w3.org/2000/svg"  viewBox="0 0 48 48" width="24px" height="24px"><path fill="#0288D1" d="M42,37c0,2.762-2.238,5-5,5H11c-2.761,0-5-2.238-5-5V11c0-2.762,2.239-5,5-5h26c2.762,0,5,2.238,5,5V37z"/><path fill="#FFF" d="M12 19H17V36H12zM14.485 17h-.028C12.965 17 12 15.888 12 14.499 12 13.08 12.995 12 14.514 12c1.521 0 2.458 1.08 2.486 2.499C17 15.887 16.035 17 14.485 17zM36 36h-5v-9.099c0-2.198-1.225-3.698-3.192-3.698-1.501 0-2.313 1.012-2.707 1.99C24.957 25.543 25 26.511 25 27v9h-5V19h5v2.616C25.721 20.5 26.85 19 29.738 19c3.578 0 6.261 2.25 6.261 7.274L36 36 36 36z"/></svg>',
            url: 'https://www.linkedin.com/sharing/share-offsite/?url=PAGE_URL&text=TEXT_SELECTION'
        }


        ])

        Sharect.config({
            facebook: true,
            twitter: true,
            twitterUsername: 'sandhya',
            backgroundColor: '#667EEA',
            iconColor: '#FFF',
            selectableElements: ['p'],
        })

        Sharect.init()


        // JavaScript code to handle dynamic content display
        function openBlog(blogId) {
            // Replace the blog content with the selected blog post
            const blogContent = document.getElementById("blogContent");
            const blogPost = getBlogPostById(blogId);

            if (blogPost) {
                blogContent.innerHTML = `
        <h2>${blogPost.title}</h2>
        <p>${blogPost.content}</p>
      `;
            }
        }


    </script>
</body>

</html>